Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis (DATA)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Benjamin Leder, MD, Massachusetts General Hospital Identifier:
First received: June 19, 2009
Last updated: November 30, 2016
Last verified: November 2016
The aim of this study is to determine whether denosumab (an FDA-approved osteoporosis therapy), in combination with teriparatide (an FDA-approved osteoporosis therapy), will increase bone mineral density more than either one alone in postmenopausal osteoporotic women.

Condition Intervention Phase
Drug: denosumab
Drug: teriparatide
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Denosumab And Teriparatide Administration Study (DATA)

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Bone Mineral Density by Dual X-ray Absorptiometry (DXA) [ Time Frame: 06/2009-02/2015 ]

Estimated Enrollment: 90
Study Start Date: June 2009
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: denosumab ONLY Drug: denosumab
denosumab: 60 mg SC every 6 months
Experimental: teriparatide (Forteo®) ONLY Drug: teriparatide
teriparatide: 20 mcg SC QD
Other Name: Forteo®
Experimental: denosumab and teriparatide (Forteo®) Drug: denosumab
denosumab: 60 mg SC every 6 months
Drug: teriparatide
teriparatide: 20 mcg SC QD
Other Name: Forteo®


Ages Eligible for Study:   45 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Must satisfy A and B and C and D below:

  • (A) Women aged > 55
  • (B) Postmenopausal
  • (C) Osteoporotic with high risk of fracture

Exclusion Criteria:

  • Confirmed serum alkaline phosphatase above upper normal limit with no explanation
  • Liver disease (AST or ALT > 2 x upper normal limit).
  • Renal disease (serum creatinine > 2.0 mg/dl).
  • Hypercalcemia (Ca >10.5 mg/dL)
  • Elevated blood PTH (intact PTH > 65 pg/ml)
  • Serum 25-OH vitamin D < 20 ng/ml
  • HCT < 32%.
  • History of malignancy (except basal cell carcinoma) or radiation therapy.
  • Significant cardiopulmonary disease including unstable coronary artery disease, stage D ACC/AHA heart failure or any other condition that the investigator deems may preclude the subject from participating safely or completing the protocol procedures.
  • Major psychiatric disease that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures.
  • Excessive alcohol use or substance abuse that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures.
  • Known congenital or acquired bone disease other than osteoporosis (including osteomalacia, hyperparathyroidism, Paget's disease)
  • Current use or use in the past 6 months of oral bisphosphonate
  • Current use or use within the past 3 months of estrogens, selective estrogen receptor modulators, or calcitonin.
  • Use of oral or parenteral glucocorticoids for more than 14 days within the past 6 months.
  • Any current or previous use of strontium or any parenteral bisphosphonate.
  • Known sensitivity to mammalian cell-derived drug products.
  • Known sensitivity to teriparatide or any of its excipients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00926380

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Benjamin Z Leder, MD Massachusetts General Hospital
Principal Investigator: Robert M Neer, MD Massachusetts General Hospital
  More Information


Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Benjamin Leder, MD, Principal Investigator, MD, Massachusetts General Hospital Identifier: NCT00926380     History of Changes
Other Study ID Numbers: 20080723
Study First Received: June 19, 2009
Last Updated: November 30, 2016

Keywords provided by Massachusetts General Hospital:
Bone Mineral Density

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on May 22, 2017